|Peer-Reviewed|December 24, 2020
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Advertisement
Articles in this issue
over 4 years ago
Article
Interview: Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Celover 4 years ago
Article
FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLCover 4 years ago
Article
Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Showover 4 years ago
Article
Contributor: A Practical Path Forward to More Patient-Centered Value AssessmentNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Overcoming Weight Bias in Health Care Systems
September 15th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
3
Metabolic Issues More Common in Patients With HIV
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5